ArticleThe World Allergy Organization journal2026
Development and validation of a clinically applicable biomarker panel for identifying autoimmune type IIb chronic spontaneous urticaria.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) includes 2 autoimmune endotypes, type I (autoallergic) and type IIb (autoimmune), which differ in pathogenesis and treatment response. However, practical criteria for distinguishing these endotypes in routine clinical practice remain limited. Objective: This study aimed to evaluate whether combinations of readily available clinical parameters facilitate identification of probable type IIb CSU. Methods: A total of 125 CSU patients were evaluated using 3 diagnostic combinations: (1) high IgG anti-thyroid peroxidase antibodies (IgG-anti-TPO) with low total IgE; (2) high IgG-anti-TPO with a positive autologous serum skin test (ASST+); and (3) low total IgE with ASST+. Clinical and laboratory features were compared between presumed endotypes. Serum cytokine profiles were analyzed and validated in an independent cohort of 40 patients. A predictive graphical model integrating clinical and laboratory variables was developed. Results: All 3 combinations identified patient subsets with features compatible with type IIb CSU, including trends toward higher disease activity (UAS7), peripheral eosinopenia and basopenia. The combination of high IgG-anti-TPO with ASST positivity was associated with the most comprehensive type IIb-compatible features. Cytokine profiles also differed between endotypes: serum IL-6 tended to be lower in possible type IIb CSU, whereas IL-17 A and TNF-α tended to be higher, compared with the remaining CSU patients. These patterns were directionally supported in the independent validation cohort. The predictive nomogram model demonstrated good discriminatory performance. Conclusions: Combinations of IgG-anti-TPO, total IgE, and ASST provide practical reference tools for identifying probable type IIb CSU, with high IgG-anti-TPO plus ASST positivity showing the highest clinical relevance. Distinct cytokine patterns further support endotype-related immune differences and may aid individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.